Skip to main content

Table 5 Inter-cohort comparison of type-specific substitution mutations across all TP53 exons

From: Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells

Mutation

CA-SMK1

NC-SMK2

NC-NON3

NC-TOT4

C > A

17 (2.0 × 10−3)*

1 (1.2 × 10−4)

0

1 (1.2 × 10−4)

C > G

1 (1.2 × 10−4)

1 (1.2 × 10− 4)

0

1 (1.2 × 10− 4)

C > T

27 (3.2 × 10−3)***

1 (1.2 × 10− 4)

1 (1.2 × 10− 4)

2 (2.4 × 10− 4)

T > A

3 (3.6 × 10− 4)

0

0

0

T > C

9 (1.1 × 10− 4)*

0

0

0

T > G

0

0

0

0

  1. 1CA-SMK; Cancer subject, present or past smoker. 2NC-SMK; Non-Cancer subject, present or past smoker. 3NC-NON; Non-Cancer subject, never smoker. 4NC-TOT; All Non-Cancer subjects, smokers and non-smokers
  2. *p < 0.05; **p < 0.01; ***p < 0.005
  3. Mutation number with prevalence in parentheses (mutations/target bp/subject) for each substitution type. Mutations were called as described in Methods section, after testing for significance of mutation VAF above background and using a VAF of 0.05% as a minimum threshold
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us